Welcome to our dedicated page for United Therapeutics SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to United Therapeutics Corporation (NASDAQ: UTHR) filings with the U.S. Securities and Exchange Commission, along with AI-generated summaries to help interpret key disclosures. United Therapeutics is a biotechnology and pharmaceutical company whose common stock trades on the Nasdaq Global Select Market, as noted in its Form 8-K reports. The company develops therapies for pulmonary arterial hypertension and related lung diseases and pursues technologies to expand the availability of transplantable organs as part of its public benefit corporation mandate.
In these SEC filings, investors can review current reports on Form 8-K that describe material events such as quarterly earnings releases, clinical milestones, share repurchase arrangements, and shareholder meeting outcomes. For example, United Therapeutics has filed 8-Ks to furnish press releases on quarterly financial results, to report positive TETON-2 clinical data for nebulized Tyvaso in idiopathic pulmonary fibrosis, and to disclose accelerated share repurchase agreements under a board-authorized share repurchase program.
Filings also document corporate governance and compensation matters, including amendments and restatements of the company’s stock incentive plan, vote results from the annual meeting of shareholders, and the listing of common stock on the Nasdaq Global Select Market under the symbol UTHR. These documents provide insight into equity compensation structures, director elections, advisory votes on executive pay, and auditor ratification.
Through this page, you can quickly locate United Therapeutics’ 8-Ks and, where available, other forms such as 10-K annual reports, 10-Q quarterly reports, and Forms 3, 4, and 5 related to insider ownership and transactions. AI-powered summaries highlight the main points of lengthy filings, explain complex sections in simpler language, and draw attention to items that often matter to investors, such as revenue drivers, capital return actions, and significant clinical or regulatory updates. Real-time updates from EDGAR ensure that new UTHR filings appear promptly, helping users monitor the company’s regulatory and disclosure record in one place.
ROTHBLATT MARTINE A reported acquisition or exercise transactions in this Form 4 filing.
UNITED THERAPEUTICS Corp reported new performance-based equity awards for Chairperson & CEO Martine A. Rothblatt. She was credited with 207,720 stock options and two blocks of performance-based restricted stock units covering 32,499 and 37,080 units.
The options are tied to average cash profit margin during 2023–2025, while the RSUs are tied to average revenue growth and clinical development performance over the same 2023–2025 period. Performance outcomes were determined in early 2026, and all earned options and RSUs are scheduled to vest on March 15, 2026, with each RSU delivering one common share at vesting.
UNITED THERAPEUTICS Corp reported that President and COO Michael Benkowitz acquired equity awards tied to multi‑year performance goals. On March 15, 2023 he was granted 99,720 performance-based stock options earned from a three-year cash profit margin target for 2023-2025, which will vest on March 15, 2026.
He was also granted 15,592 performance-based restricted stock units tied to average revenue growth for 2023-2025 and 17,790 performance-based restricted stock units tied to clinical development performance for 2023-2025; both awards were earned based on performance and will vest on March 15, 2026. Each restricted stock unit converts into one share of common stock after vesting.
United Therapeutics reported that CFO and Treasurer James Edgemond acquired new equity awards made up of stock options and performance-based restricted stock units. He received 58,170 stock options and two tranches of restricted stock units totaling 9,098 and 10,380 units.
The stock options are tied to a three-year performance condition based on average cash profit margin during 2023-2025, with performance determined in February 2026. One restricted stock unit grant is tied to average revenue growth during 2023-2025, with performance also determined in February 2026, while the other is tied to clinical development performance during 2023-2025, determined in January 2026.
All earned awards will vest on March 15, 2026. Each restricted stock unit gives the right to receive one share of United Therapeutics common stock after vesting, and the units do not have an expiration date.
Morgan Stanley Smith Barney LLC submitted a notice regarding the proposed sale of 1,000 common shares02/25/2026 and cash proceeds indicated. The filing also lists two prior sales by Christopher Causey:
UNITED THERAPEUTICS Corp director Christopher Causey reported option exercises and a share sale. He exercised stock options for 1,000 shares on
On the same date, he sold 1,000 shares of common stock at
United Therapeutics Corporation reported strong fourth quarter and full year 2025 results, highlighted by record annual revenues of
Growth was driven mainly by Tyvaso DPI, with 2025 sales of
United Therapeutics is a public benefit corporation focused on treating pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD), and other serious diseases while developing manufactured organs and organ alternatives.
The company’s core drugs are treprostinil-based therapies Tyvaso DPI, Nebulized Tyvaso, Remodulin, and Orenitram, plus oncology drug Unituxin and PDE‑5 inhibitor Adcirca. In 2025, combined Tyvaso DPI and Nebulized Tyvaso net product sales were
Pipeline highlights include positive phase 3 TETON 2 data for Nebulized Tyvaso in idiopathic pulmonary fibrosis (IPF) and the global phase 3 ADVANCE OUTCOMES study of oral prostacyclin agonist ralinepag in PAH. Beyond drugs, the company is advancing xenotransplantation (UKidney and UThymoKidney clinical studies), regenerative programs such as miroliverELAP, and ex vivo lung perfusion services, while investing in low‑emission air transport for organ delivery.
UNITED THERAPEUTICS Corp president and COO Michael Benkowitz reported option exercises and related sales of common stock through trusts on February 23, 2026. Trusts associated with him exercised options for 9,375 and 5,065 shares, then sold those same amounts in open-market transactions at $472.126 per share.
The activity was carried out under a Rule 10b5-1 trading plan that was previously established and these are the final transactions under that plan. Following these indirect trust transactions, Benkowitz directly holds 2,648 shares of United Therapeutics common stock.
UNITED THERAPEUTICS Corp executive Paul A. Mahon exercised stock options and sold shares in a planned transaction. He exercised options for 8,300 shares of common stock at a price of $146.03 per share and received the underlying shares.
On the same date, he sold 8,300 shares of common stock in multiple open-market trades at weighted average prices ranging from about $471 to $479 per share under a pre-arranged Rule 10b5-1 plan entered on August 11, 2025. After these transactions, he directly owned 36,781 shares of UNITED THERAPEUTICS common stock.
Paul Mahon submitted a Form 144 proposing to sell 8,300 common shares via a stock options exercise with an intended transaction date of